Version May 2024
Allergic conjunctivitis: Ophthalmic:
Rx labeling: Instill 1 drop into each eye once daily.
OTC labeling: Instill 1 drop into affected eye(s) once daily.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Alcaftadine: Pediatric drug information")
Allergic conjunctivitis/ocular itching: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) once daily.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely to be necessary due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely to be necessary due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%:
Central nervous system: Headache (<3%)
Ophthalmic: Burning sensation of eyes (<4%), eye irritation (<4%), eye pruritus (<4%), eye redness (<4%), stinging of eyes (<4%)
Respiratory: Nasopharyngitis (<3%)
<1%, postmarketing, and/or case reports: Allergic dermatitis, blurred vision, drowsiness, erythema of eyelid, eye discharge, eyelid edema, facial edema, hypersensitivity, increased lacrimation, swelling of eye
Hypersensitivity to alcaftadine or any component of the formulation.
OTC labeling: When used for self-medication, do not use if you are sensitive to any ingredient of the formulation or to treat contact lens irritation.
Special populations:
• Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting. Not for the treatment of contact lens irritation; do not wear contact lens if eye is red.
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only. To avoid eye injury and contamination, do not touch dropper tip to eyelids or any surface.
• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and notify health care provider if eye pain or changes in vision occur, redness of the eye increases, or itching worsens or lasts >72 hours.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic:
Lastacaft: 0.25% (3 mL [DSC], 5 mL) [contains benzalkonium chloride, edetate (edta) disodium]
No
Solution (Lastacaft Ophthalmic)
0.25% (per mL): $2.61
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For topical ophthalmic use only. Contact lenses should be removed prior to application, and may be reinserted 10 minutes after administration. Separate administration of other ophthalmic agents by 5 minutes. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip with affected eye(s).
Ophthalmic: For topical ophthalmic use only. Contains benzalkonium chloride; contact lenses should be removed prior to application and may be reinserted 10 minutes after administration. Separate administration of other ophthalmic agents by 5 minutes. Do not insert contacts if eyes are red. Avoid contamination; do not touch the applicator tip to eye, eyelid, or other surfaces.
Allergic conjunctivitis:
Rx labeling: Prevention of itching associated with allergic conjunctivitis.
OTC labeling: Temporary relief of itchy eyes due to animal dander and hair, grass, pollen, and ragweed.
None known.
There are no known significant interactions.
Adverse events were not observed in animal reproduction studies.
If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).
It is not known if alcaftadine is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.
Direct H1-receptor antagonist and inhibitor of histamine release from mast cells
Absorption: Minimal systemic absorption
Protein binding: ~40%; Carboxylic acid (metabolite): ~60%
Metabolism: Non-CYP450 cytosolic enzymes to the active metabolite carboxylic acid
Half-life elimination: Carboxylic acid: ~2 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
